Bosnia and HerzegovinaTuberculosis profile
Population  2015 3.8 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.12 (0.1–0.13) 3 (2.7–3.4)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0–0.06)
Incidence  (includes HIV+TB) 1.4 (1.1–1.8) 37 (29–47)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.1 (0.06–0.15)
Incidence (MDR/RR-TB)** 0.01 (<0.01–0.019) 0.26 (0.04–0.5)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.044 (0.02–0.068) 0.56 (0.38–0.74) 0.6 (0.4–0.81)
Males 0.044 (0.026–0.062) 0.78 (0.59–0.96) 0.82 (0.62–1)
Total 0.088 (0.057–0.12) 1.3 (1.2–1.5) 1.4 (1.1–1.8)
TB case notifications, 2015  
Total cases notified 1 095
Total new and relapse 1 092
          - % tested with rapid diagnostics at time of diagnosis 100%
          - % with known HIV status 19%
          - % pulmonary 89%
          - % bacteriologically confirmed among pulmonary 70%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 77% (62–98)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.08 (0.06–0.11)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  6
(0–12)
Estimated % of TB cases with MDR/RR-TB 0.51% (0.11–1.5) 1.6% (0.04–8.5)  
% notified tested for rifampicin resistance 66% 54% 708
MDR/RR-TB cases tested for resistance to second-line drugs   1
Laboratory-confirmed cases MDR/RR-TB: 3, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 1, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 77% 1 196
Previously treated cases, excluding relapse, registered in 2014    
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 100% 1
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 67%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 12
Funding source: 93% domestic, 7% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data